Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27416287 | 0.89 | TDP1 (0.48) | TDP1P2RY12KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL2225671 | 0.85 | KDM4E (0.51) | P2RY12CYP2C9CYP2C19KDM4EHSD17B10 | |
| SCHEMBL3954184 | 0.84 | P2RY12 (0.49) | P2RY12CYP2C9CYP2C19KDM4EHSD17B10 | |
| SCHEMBL30908249 | 0.84 | TDP1 (0.44) | TDP1KDM4EL3MBTL1GAAALDH1A1 | |
| SCHEMBL2129547 | 0.84 | TDP1 (0.44) | TDP1KDM4EL3MBTL1GAAALDH1A1 | |
| SCHEMBL11194084 | 0.83 | P2RY12 (0.48) | TDP1P2RY12CYP2C9CYP2C19KDM4E | |
| SCHEMBL14955100 | 0.83 | P2RY12 (0.48) | TDP1P2RY12CYP2C9CYP2C19KDM4E | |
| SCHEMBL12467752 | 0.81 | L3MBTL1 (0.61) | TDP1P2RY12CYP2C9CYP2C19KDM4E | |
| SCHEMBL31050105 | 0.80 | ALDH1A1 (0.61) | TDP1P2RY12CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL990850 | 0.80 | CYP2C9 (0.53) | TDP1P2RY12CYP2C9CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731207-A2 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | Merck Sharp & Dohme LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2025006293-A2 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | MERCK SHARP & DOHME LLC (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20230338429-A1 | COMPOUNDS AND USE THEREOF IN THE EXPANSION OF STEM CELLS AND/OR PROGENITOR CELLS | UNIVERSITE DE MONTREAL (CA) | 2023-10-26 | — | — | US | disclosed |
| US-11696928-B2 | Compounds and use thereof in the expansion of stem cells and/or progenitor cells | UNIVERSITE DE MONTREAL (CA) | 2023-07-11 | — | — | US | disclosed |
| US-20230069174-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-03-02 | — | — | US | disclosed |
| US-20230069174-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-03-02 | — | — | US | disclosed |
| EP-4074711-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2022-10-19 | — | — | EP | disclosed |
| CN-114901658-A | Nitrogen-containing heterocyclic ring autotaxin inhibitor, and composition and application thereof | 四川海思科制药有限公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021115375-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | 四川海思科制药有限公司 | 2021-06-17 | — | — | WO | disclosed |
| US-20200323923-A1 | COMPOUNDS AND USE THEREOF IN THE EXPANSION OF STEM CELLS AND/OR PROGENITOR CELLS | UNIVERSITE DE MONTREAL (CA) | 2020-10-15 | — | — | US | disclosed |
| EP-1836189-A1 | NOVEL PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006073361-A9 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007070393-A2 | MGLUR1 ANATGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| CN-1894225-A | (3, 4-disubstituted) propanoates as sphingosine 1-phosphate (endothelial differentiation gene) receptor agonists | MERCK & CO INC (US) | 2007-01-10 | — | — | CN | disclosed |
| EP-1697333-A1 | (3,4-DISUBSTITUTED)PROPANOIC CARBOXYLATES AS S1P (EDG) RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006002051-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS | SCHERING CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005058848-A1 | (3,4-DISUBSTITUTED)PROPANOIC CARBOXYLATES AS S1P (EDG) RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696928-B2 | Compounds and use thereof in the expansion of stem cells and/or progenitor cells | MCL1, CD47, BMI1 | TDP1 2673/4885P2RY12 2853/4885CYP2C9 4756/4885 |
| US-20230338429-A1 | COMPOUNDS AND USE THEREOF IN THE EXPANSION OF STEM CELLS AND/OR PROGENITOR CELLS | MCL1, CD47, BMI1 | TDP1 2673/4885P2RY12 2853/4885CYP2C9 4756/4885 |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | GRM1, GRM4, GRIA1 | TDP1 1348/4885P2RY12 309/4885CYP2C9 2337/4885 |
| US-20230069174-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | ENPP2, NMT2, NMT1 | TDP1 954/4885P2RY12 4352/4885CYP2C9 3968/4885 |
| US-20200323923-A1 | COMPOUNDS AND USE THEREOF IN THE EXPANSION OF STEM CELLS AND/OR PROGENITOR CELLS | MCL1, CD47, BMI1 | TDP1 2673/4885P2RY12 2853/4885CYP2C9 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.